Navigation Links
Marijuana administration after a traumatic experience prevents post-traumatic stress symptoms
Date:9/21/2011

Cannabinoids (marijuana) administration after experiencing a traumatic event blocks the development of post-traumatic stress disorder (PTSD)-like symptoms in rats, according to a new study conducted at the University of Haifa and published in the journal Neuropsychopharmacology.

"We found that there is a 'window of opportunity' during which administering synthetic marijuana helps deal with symptoms simulating PTSD in rats," said Dr. Irit Akirav of the University of Haifa's Department of Psychology, who led the study.

In the study, which Dr. Akirav conducted with research student Eti Ganon-Elazar, the researchers set out to examine how administering cannabinoids (synthetic marijuana) affects the development of PTSD-like symptoms in rats, whose physiological reactions to traumatic and stressful events is similar to human reactions.

In the first part of the study, the researchers exposed a group of rats to extreme stress, and observed that the rats did indeed display symptoms resembling PTSD in humans, such as an enhanced startle reflex, impaired extinction learning, and disruption of the negative feedback cycle of the stress-influenced HPA axis.

The rats were then divided into four groups. One was given no marijuana at all; the second was given a marijuana injection two hours after being exposed to a traumatic event; the third group after 24 hours and the fourth group after 48 hours.

A week later, the researchers examined the rats and found that the group that had not been administered marijuana and the group that got the injection 48 hours after experiencing trauma continued to display PTSD symptoms as well as a high level of anxiety.

By contrast, the PTSD symptoms disappeared in the rats that were given marijuana 2 or 24 hours after experiencing trauma, even though these rats had also developed a high level of anxiety.

"This indicates that the marijuana did not erase the experience of the trauma, but that it specifically prevented the development of post-trauma symptoms in the rat model," said Dr. Akirav, who added that the results suggest there is a particular window of time during which administering marijuana is effective. Because the human life span is significantly longer than that of rats, Dr. Akirav explained, one could assume that this window of time would be longer for humans.

The second stage of the study sought to understand the brain mechanism that is put into operation during the administering of marijuana. To do this, they repeated stage one of the experiment, but after the trauma they injected the synthetic marijuana directly into the amygdala area of the brain, the area known to be responsible for response to trauma. The researchers found that the marijuana blocked development of PTSD symptoms in these cases as well. From this the researchers were able to conclude that the effect of the marijuana is mediated by a CB1 receptor in the amygdala.


'/>"/>

Contact: Rachel Feldman
rfeldman@univ.haifa.ac.il
972-482-88722
University of Haifa
Source:Eurekalert

Related medicine news :

1. Bodys natural marijuana-like chemicals make fatty foods hard to resist
2. 2 talks with teens leads to less marijuana use for at least a year
3. Medical Marijuana Might Slow Thinking Among MS Patients
4. National anti-drug campaign succeeds in lowering marijuana use, study suggests
5. Marijuana Use Up Among Eighth Graders
6. Fake Marijuana Users Showing Up in Emergency Rooms
7. Legalizing marijuana in California would not substantially cut cartel revenues, study finds
8. Fathers incarceration associated with elevated risks of marijuana and other illegal drug use
9. Use of Marijuana, Ecstasy, Methamphetamine on Rise in U.S.
10. Risk of marijuanas gateway effect overblown, new UNH research shows
11. Smoked Marijuana May Ease Chronic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch ... for colleges and universities at the APPA 2017 Annual Conference and Exhibition ... tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... 21, 2017 , ... “Kids aren't born knowing how to regulate their emotions ... Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help with that ... July 21st. , The kit uses colorful, engaging and educational illustrations and games ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: